TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05484648
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone has been used to generally favorable results in peripheral nerve blocks as adjunct. Several studies have reported prolongation in the duration of ropivacaine, mepivacaine and bupivacaine when used in combination with dexamethasone.~Various mechanisms for the beneficial adjunctive effect of dexamethasone with Local Anesthetics (LA) have been proposed. One theory suggests that the improved analgesia and increased blockade duration is due to its anti-inflammatory properties. It also acts as a local vasoconstrictor and thus may act by reducing LA absorption. Furthermore, it also increases the activity of inhibitory potassium channels on nociceptive C-Fibers.
Study: NCT05484648
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine is another promising drug being used as a local anaesthetic adjuvant in peripheral nerve blocks. It is an alpha-2 agonist, which has shown to have prolonged duration of postoperative analgesia when given with LA for peripheral nerve blocks with other beneficial effects such as reducing the opioid consumption. Alpha-2-agonists such as dexmedetomidine cause hyperpolarization-activated cation currents which inhibit the transmission of nociceptive fibers.
Study: NCT05889299
Drug: OMS906 study drug
Normalized name: ethanol
DrugBank: OMS906 (DB17722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OMS906 study drug dose repeat-dose 5mg/kg SC administration at 4-week intervals
Study: NCT05920642
Drug: Intrathecal morphine administration
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of morphine into the spinal canal.
Study: NCT06433713
Drug: Lidocaine IV
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: They received IV infusion of 2 mg/kg per hour of lidocaine starting with skin incision, which was maintained until skin closure. This was done using a syringe pump with the calculated amount of lidocaine added to 50 ml of normal saline infused at a rate of 50 ml/hr.
Study: NCT00002381
Drug: Nelfinavir mesylate
Normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002381
Drug: Nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002381
Drug: Stavudine
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06020352
Drug: KN046 plus Axitinib
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: KN046 combined with axitinib as a neoadjuvant treatment regimen
Study: NCT06515678
Drug: arm R - angiotensin receptor blockers ARB
Normalized name: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients with angiotensin receptor blocker (ARB) before or within 6 months following debulking surgery.~ARBs will be defined as any drugs from the Anatomical Therapeutic Classification C09CA with an indication for hypertension, including but not limited to: losartan, valsartan, irbesartan, candesartan or olmesartan medoxomil.
Study: NCT05403476
Drug: FE 999049
Normalized name: Fe
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FE 999049 is administered as single daily subcutaneous injections of 12 μg for 6 months.
Study: NCT06009393
Drug: SHR-1918
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three administration
Study: NCT04074096
Drug: Binimetinib Oral Tablet
Normalized name: binimetinib Oral Tablet
DrugBank: Binimetinib (DB11967)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All patients: binimetinib 45 mg PO BID.
Study: NCT04074096
Drug: Encorafenib Oral Capsule
Normalized name: encorafenib Oral Capsule
DrugBank: Encorafenib (DB11718)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All patients: encorafenib 450 mg PO QD
Study: NCT04074096
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All patients: pembrolizumab 200 mg IV Q3W
Study: NCT05587699
Drug: CKD-843 A 45mg(Multiple dose)
Normalized name: sodium acetate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 Injection/3 Month, 3 times Injections
Study: NCT05587699
Drug: CKD-843 A 45mg
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Injection
Study: NCT05587699
Drug: CKD-843 A 55mg(Multiple dose)
Normalized name: sodium acetate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 Injection/3 Month, 3 times Injections
Study: NCT05587699
Drug: CKD-843 A 55mg
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Injection
Study: NCT05461235
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2mg/kg or 200mg,iv,q3w
Study: NCT05461235
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3mg/kg or 240mg,iv,q2w
Study: NCT05461235
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg,iv,q3w
Study: NCT05461235
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3mg/kg or 240mg,iv,q2w
Study: NCT05461235
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg,iv,q2w or q3w;3mg/kg,iv,q3w
Study: NCT05461235
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg,iv,q3w
Study: NCT06140732
Drug: camrelizumab and apatinib
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: camrelizumab 200 mg iv/ q2w+ apatinib 375mg oral qd
Study: NCT05113810
Drug: HCQ01
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HCQ01 is a sterile, clear and colorless, ready-to-use aqueous nebulizer solution. Hydroxychloroquine sulfate administered via nebulization
Study: NCT05824559
Drug: ME-344
Normalized name: ME-344
DrugBank: ME-344 (DB13062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ME-344 will be administered intravenously (IV)
Study: NCT05824559
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab will be administered intravenously (IV)
Study: NCT04551066
Drug: parsaclisib
Normalized name: Parsaclisib
DrugBank: Parsaclisib (DB14867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: parsaclisib will be administered QD orally
Study: NCT04551066
Drug: ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ruxolitinib will be administered BID orally
Study: NCT06414577
Drug: Irinotecan Liposomal combined With Nituzumab
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan liposomal: 70mg/m2, ivgtt, d1; Nituzumab: 400 mg, igvtt, d1 One treatment cycle every two weeks for up to 8 cycles, or until disease progression, intolerable toxicity, death, and investigator judgment of no further benefit
Study: NCT05319587
Drug: Liposomal Annamycin
Normalized name: Annamycin
DrugBank: Annamycin (DB06420)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-hour intravenous infusion liposomal annamycin daily for 3 consecutive days followed by 18 days off study drug (i.e., one treatment cycle = 21 days).
Study: NCT05319587
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered during cycle 1 at a dose of 2.0 g/m2/day by 4 hours IV infusion for 5 consecutive days and this dose will remain constant for all cohorts, including the expansion phase.
Study: NCT06397235
Drug: DEB-TACE+HAIC
Normalized name: triclosan
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CalliSpheres (100-300 µm) loaded with pirarubicin for transarterial chemombolization: Typically, one vial of the beads was loaded with 60 mg pirarubicin. If blushed tumors is still visible after the embolization with one vial of beads, regular microspheres (8spheres) with diameters of 100-700 μm are additionally injected.~RALOX-based regimen for hepatic arterial infusion chemotherapy: oxaliplatin, 85 mg/m2 infusion for 2 hours; Raltitrexed, 3 mg/m2 infusion for 0.5 hour.
Study: NCT06397235
Drug: DEB-TACE
Normalized name: triclosan
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CalliSpheres (100-300 µm) loaded with pirarubicin for transarterial chemombolization: Typically, one vial of the beads was loaded with 60 mg pirarubicin. If blushed tumors is still visible after the embolization with one vial of beads, regular microspheres (8spheres) with diameters of 100-700 μm are additionally injected.
Study: NCT05157581
Drug: Methoxsalen Injection
Normalized name: Methoxsalen Injection
DrugBank: Methoxsalen (DB00553)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methoxsalen is a light-sensitizing sterile compound added to the collected white blood cells and plasma during ECP.
Study: NCT06299761
Drug: BBI-825
Normalized name: BBIBP-CorV
DrugBank: BBIBP-CorV (DB15807)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral RNR inhibitor
Study: NCT05628883
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive an intravenously (IV) infusion of Fludarabine 25 mg/m2 for approximately 15 to 30 minutes for 5 days, prior to T-Cell infusion
Study: NCT05628883
Drug: Interleukin-2
Normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive Interleukin-2 (IL-2) 600 000 IU/kg intravenously every 8 to 12 hours beginning within 24 hours after T-cell infusion.
Study: NCT05621174
Drug: Dexamfetamine
Normalized name: Dexamfetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magisterial Dexamfetamine
Study: NCT05621174
Drug: Dexamfetamine
Normalized name: Dexamfetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tentin
Study: NCT06350097
Drug: Osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Arm 1: Osimertinib 80 mg QD as oral tablet with Datopotamab Deruxtecan 6mg/kg as i.v. infusion.~Arm 2: Osimertinib 80 mg QD as oral tablet .
Study: NCT06350097
Drug: Datopotamab Deruxtecan
Normalized name: Datopotamab deruxtecan
DrugBank: Datopotamab deruxtecan (DB16410)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib 80 mg QD as oral tablet with Datopotamab Deruxtecan 6mg/kg as i.v. infusion.
Study: NCT05030493
Drug: mFOLFOX6 + panitumumab combination therapy
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab oxaliplatin (OXA), levofolinate calcium (l-LV), panitumumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
Study: NCT05030493
Drug: mFOLFOX6 + bevacizumab combination therapy
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab oxaliplatin (OXA), levofolinate calcium (l-LV), bevacizumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
Study: NCT05900895
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will be treated with olaparib at the approved doses for the treatment of subtypes of breast cancer or at reduced dose/frequency for participants with moderate renal impairment.
Study: NCT00057395
Drug: Aroplatin (Liposomal NDDP, L-NDDP)
Normalized name: Carboplatin
DrugBank: Aroplatin (DB17319)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04895098
Drug: statin and ezetimibe combination therapy
Normalized name: atorvastatin and ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Receiving statins (atorvastatin/rosuvastatin or others) in combination with ezetimibe 10mg/day in a stable dosing regimen (without changing the dose of the therapy and/or replacing the statin) for 3 or more months at the time of enrolment in the study.
Study: NCT05100069
Drug: Brigatinib
Normalized name: Brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Brigatinib Tablets
Study: NCT05522673
Drug: 11(R)-rolipram
Normalized name: R
DrugBank: Rolipram (DB01954)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injected IV followed by PET scanning
Study: NCT05635487
Drug: SHR-A1811
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-A1811
Study: NCT05635487
Drug: Pyrotinib
Normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrotinib
Study: NCT06379867
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.4 g, Oral administration with 240 mL
Study: NCT05517330
Drug: Afatinib
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 30mg PO QD
Study: NCT06446206
Drug: Adebrelimab, paclitaxel, carboplatin, bevacizumab, fluzoparib
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adebrelimab plus paclitaxel, carboplatin and bevacizumab induction therapy followed by maintenance therapy with adebrelimab plus fluzoparib and bevacizumab.
Study: NCT06252857
Drug: Imiquimod Topical
Normalized name: imiquimod topical
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Topical application of imiquimod (once daily, 5 days a week, during 6 weeks) versus surgical excision.
Study: NCT05096702
Drug: Tafenoquine
Normalized name: tafenoquine
DrugBank: Tafenoquine (DB06608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tafenoquine 300 mg (2x150mg tablets)
Study: NCT05096702
Drug: Primaquine
Normalized name: Primaquine
DrugBank: Primaquine (DB01087)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily primaquine adjusted by weight (0.5 mg/kg/day for 7 days)
Study: NCT05096702
Drug: Primaquine
Normalized name: Primaquine
DrugBank: Primaquine (DB01087)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly primaquine adjusted by weight (0.75mg/kg/week for 8 weeks)
Study: NCT04904965
Drug: Propofol Group 1
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 2.0 mg/kg/hr per 10 min
Study: NCT04904965
Drug: Propofol Group 2
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 4.0 mg/kg/hr per 10 min
Study: NCT04904965
Drug: Propofol Group 3
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 6.0 mg/kg/hr per 10 min
Study: NCT04904965
Drug: Propofol Group 4
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 8.0 mg/kg/hr per 10 min
Study: NCT05719051
Drug: Albumin infusion
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin infusion was administrated according to the standard clinical practice
Study: NCT05366192
Drug: Nirmatrelvir and ritonavir stage 1
Normalized name: nirmatrelvir and ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nirmatrelvir 150mg qd (another 75mg will be supplied after hemodialysis treatment) and ritonavir 100mg bid everyday for 5 days.
Study: NCT05366192
Drug: Nirmatrelvir and ritonavir stage 2
Normalized name: nirmatrelvir and ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nirmatrelvir 300mg qd (another 150mg will be supplied after hemodialysis treatment) and ritonavir 100 bid everyday for 5 days.
Study: NCT05341570
Drug: BPI-21668
Normalized name: BPI-3016
DrugBank: BPI-3016 (DB15158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive BPI-21668 until disease progression
Study: NCT00347035
Drug: brimonidine
Normalized name: Brimonidine
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT06070116
Drug: Ivermectin w/ Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be given a dose of oral Ivermectin (IVM) (150 µg/kg) plus Albendazole (ALB) (400 mg)
Study: NCT06070116
Drug: Ivermectin + Diethylcarbamazine + Albendazole
Normalized name: diethylcarbamazine
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be given a dose of oral Ivermectin (IVM) (150 µg/kg), Diethylcarbamazine (DEC) (6 mg/kg) and Albendazole (ALB) (400 mg)
Study: NCT06070116
Drug: Moxidectin + Albendazole
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be given a dose of oral Moxidectin (Mox) (8 mg) plus Albendazole (ALB) (400 mg)
Study: NCT06070116
Drug: Moxidectin + Diethylcarbamazine + Albendazole
Normalized name: diethylcarbamazine
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be given a dose of oral Moxidectin (Mox) (8 mg), Diethylcarbamazine (DEC) (6 mg/kg) and Albendazole (ALB) (400 mg)
Study: NCT04603391
Drug: dl-Methylphenidate plus Cannabidiol
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be administered one 10 mg tablet of dl-methylphenidate (Ritalin®) plus 7.5 mL Epidiolex® solution
Study: NCT04603391
Drug: dl-Methylphenidate plus Cannabidiol Placebo solution
Normalized name: cannabidiol Oral Solution
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be administered one 10 mg tablet of dl-methylphenidate (Ritalin®) plus 7.5 mL of Epidiolex® placebo solution
Study: NCT05896046
Drug: SHR-1701
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase I: 30-150 mg/kg, IV over 30 minutes. Phase II: recommended dose from phase I trial, IV over 30 minutes.
Study: NCT00011479
Drug: Abacavir sulfate
Normalized name: Abacavir Sulfate
DrugBank: Abacavir (DB01048)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT05052528
Drug: Fludarabine Phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT05001061
Drug: Misoprostol Pill
Normalized name: misoprostol Pill
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sublingual versus vaginal Misoprostol in termination of first trimester missed abortion
Study: NCT05680194
Drug: Bisphosphonate
Normalized name: Bisphosphonate
DrugBank: [{(5-Chloro-2-Pyridinyl)Amino} Methylene]-1,1-Bisphosphonate (DB03649)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisphosphonate
Study: NCT04965129
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will be given fish oil with a dose of of 2.100 mg of EPA and 924 mg of DHA, in four tablet twice daily for four mounths.
Study: NCT04944888
Drug: Eliglustat
Normalized name: Eliglustat
DrugBank: Eliglustat (DB09039)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eliglustat will be given to enrolled patients at dose of 84mg daily (dose 1) , and then at dose of 84mg twice daily (dose 2).
Study: NCT04944888
Drug: Immune checkpoint inhibitor
Normalized name: Anti-tim3 checkpoint inhibitor mbg453
DrugBank: Sabatolimab (DB16322)
Approvals — FDA: no, EMA: no, PMDA: no
Description: immune checkpoint inhibitor (physician decided).
Study: NCT05536193
Drug: Topical Metformin Emulgel and salicylic acid
Normalized name: metformin and ertugliflozin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Combination Product: Topical metformin emulgel topical metformin emulgel will be used on the left side of the face twice daily (home use).~Procedure/Surgery: Salicylic acid Patients will have salicylic acid 30% peeling on the right side of the face as a peeling session every two weeks. Sessions will be done by well trained physician.~Other Names:~• 2-hydroxybenzoic acid
Study: NCT05684653
Drug: Orelabrutinib Tablets
Normalized name: acalabrutinib Oral Tablet
DrugBank: Orelabrutinib (DB16272)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg, single oral dose
Study: NCT04870827
Drug: 13N Amonia
Normalized name: ammonia (13N)
DrugBank: Ammonia (DB11118)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered during PET/CT scans
Study: NCT06581315
Drug: Donafenib
Normalized name: DONAFENIB
DrugBank: CM-4307 (DB15414)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donafenib 100 mg twice daily (BID)
Study: NCT04782804
Drug: PD-1 Antibody（Tislelizumab）
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 Antibody（Tislelizumab, 200mg） was given q3w iv.
Study: NCT05741086
Drug: Evolocumab
Normalized name: Evolocumab
DrugBank: Evolocumab (DB09303)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: evolocumab (140 mg every 2 weeks)
Study: NCT05741086
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 20-40mg
Study: NCT05632224
Drug: Aprepitant
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The drug is given 1 hour before the start of the surgery
Study: NCT05632224
Drug: Granisetron
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The drug is given 10 minutes before the patients's extubation
Study: NCT04923620
Drug: cetuximab+mFOLFOX6
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: cetuximab 500mg/m2 d1 Oxaliplatin 85mg/m2 d1 Calcium Folinate 400mg/m2 d1 5-fluorouridine 400mg/m2 d1 5-fluorouridine 2400mg/m2 46h q2w, 6 cycles
Study: NCT04824417
Drug: Itraconazole 200 mg
Normalized name: itraconazole 200 MG
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control
Study: NCT04824417
Drug: Voriconazole 200mg
Normalized name: VORICONAZOLE 200MG TAB
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparator
Study: NCT02493322
Drug: Olmesartan medoxomil 20mg + Chlortalidone 25mg
Normalized name: olmesartan medoxomil 20 MG
DrugBank: Olmesartan (DB00275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet a day
Study: NCT04861558
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Injection of 360 mg/m2